Takeda PharmaceuticalSee all their emails

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

A real announcement email from Takeda Pharmaceutical. Captured August 24, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 email from Takeda Pharmaceutical screenshot

Captured Announcement

Takeda Pharmaceutical announces the approval of ORZEYFUL in Japan for narcolepsy type 1.

Top header with Takeda logo, split-style press release hero banner, clean white content area with headline, publication date, text link CTA, and a feedback section with rating emojis.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.